Welcome to PsychU!

Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder

Loading Events

Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder

Schizophrenia and Bipolar Disorder have a significant burden that is expected to have escalated due to COVID-19. People with serious mental illness are at increased risk of COVID-19 and have higher rates of hospitalization, morbidity, and mortality. Drs. Correll and Chen will discuss how the pandemic has affected patients with schizophrenia and bipolar disorder, including access to long-acting injectable antipsychotics.

Moderator:

Gina Lau, PharmD
Regional Medical Lead, Otsuka Pharmaceutical Development & Commercialization, Inc.

Featuring

  • Christoph Correll, MD

    Professor of Psychiatry and Molecular Medicine; The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY; Professor and Chair​; Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy​; Charité University Medicine Berlin​, Berlin, Germany

  • Maxine Chen , PhD

    Director, U.S. Medical Affairs, Otsuka Pharmaceutical Development & Commercialization

  • Gina Lau, PharmD (OPDC)

    Regional Medical Lead

Christoph Correll, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. Maxine Chen, PhD and Gina Lau, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.

Registration

Related Resources